Extract

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.

Inclusion criteria

• pulmonary hypertension

Country

• Australia
• Austria
• Belgium
• Canada
• China
• Czech Republic
• France
• Germany
• Italy
• Netherlands
• Spain
• Switzerland
• United Kingdom
• United States

Links

• nct
• ictrp